pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 1·1 min read
save

FDA permits Zyn nicotine pouches to be marketed as safer than cigarettes

Jul 1, 2026·read at STAT ↗RegulatoryPositive

The U.S. Food and Drug Administration announced that Zyn's nicotine pouches can be advertised as a safer alternative to traditional cigarettes. The decision reflects the agency's view that the pouches expose users to fewer harmful smoke constituents than combustible tobacco products.

While the FDA allows the reduced‑risk claim, it notes that the products still deliver nicotine and are not risk‑free. The ruling is expected to shape how Zyn and similar smokeless tobacco brands position themselves in the market.

The article also mentions other health‑policy topics, including the influence of the alcohol industry on public policy and new AI tools for scientists, but the primary focus is the regulatory clearance for Zyn's marketing claim.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “FDA says Zyn can market its pouches as safer than cigarettes”

read at STAT ↗
1,083 words · retrieved Jul 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Moderna, Inc.2PFIZERUltragenyx Pharmaceutical Inc.
drugs
nicotine3nicotine ER3DisPATCH
topics
Oncology7Cardiology2Vaccine2Vaccines2mRNA Therapeutic2COPDInfectious DiseaseNSCLCPsychiatry & CNSPulmonologyRare Disease

related stories

  • Dec 22Fierce Biotech Fundraising Tracker '26: Soufflé cooks up $135M; Matchpoint makes $150MFierce Biotech
  • 5d agoCaribou layoffs could wipe out 90% of staffBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Jun 1Opinion: What should hospitals do when patients demand unvaccinated donor blood?STAT
  • 1d agoBioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survivalBioSpace